Open Access<p>Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic</p>
Author(s) -
Nandeeta Samad,
Temitayo Eniola Sodunke,
Hasan Al Banna,
Ashmita Sapkota,
Aneeka Nawar Fatema,
Katia Iskandar,
Dilshad Jahan,
Timothy Craig Hardcastle,
Tanziusrat,
Tajkera Sultana Chowdhury,
Mainul Haque
Publication year - 2020
Publication title -
risk management and healthcare policy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.828
H-Index - 22
ISSN - 1179-1594
DOI - 10.2147/rmhp.s281388
Subject(s) - covid-19 , pandemic , convalescent plasma , virology , software deployment , medicine , intensive care medicine , computer science , infectious disease (medical specialty) , outbreak , disease , operating system
The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy's efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy's availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT's effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.